Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer
An Austrian Multicenter Study
Recent publication
Physicians tested the effectiveness of a triple therapy for metastatic hormone-sensitive prostate cancer in an Austrian mutli-centre trail. The combination of androgen deprivation therapy, androgen pathway inhibitor and chemotherapy had previously been shown to be superior in randomised clinical trials. The researchers confirmed the results of the clinical trials with real-life data. The University Hospital Krems was involved in this registry study with Dr Sonia Vallet from the Clinical Deivision of Internal Medicine 2. The results have been published open access in the journal "Clinical Genitourinary Cancer".
Kafka M, Giannini G, Artamonova N, Neuwirt H, Ofner H, Kramer G et al. Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study. Clinical Genitourinary Cancer. 2024 Jan 4. Epub 2024 Jan 4. doi: 10.1016/j.clgc.2023.12.018
OÄ PD Dr. Sonia Vallet
Division of Molecular Oncology and Hematology, Division of Internal Medicine 2 (University Hospital Krems)
